Plant Health Care - Leading the field
Plant Health Care expects to gain the first US regulatory approval for one of the products in its New Technology portfolio, PHC279, a PREtec (plant response elicitor) in 2020, leading to market launch in 2021. The PREtec products, which address markets worth over US$5bn, complement the company’s existing range of biological products for boosting plant yields, which are already approved for sale in 16 countries.Plant Health Care is a provider of proprietary agricultural biological products and technology solutions. Co. is organized in two lines of business: New Technology, which focuses on the deployment of its proprietary Plant Response Elicitor technology to invent and develop short chains of amino acids, or peptides; and Commercial, which focuses on selling proprietary biological products that are applied to soil, seeds or plants. Co. has three principal Harpin aA products: N-Hibit, which is a seed treatment application for row crops; ProAct, which is a foliar application for row crops; and Employ, which is a foliar application for specialty crops.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.